We purified an 80-kDa Ca 2ϩ -independent phospholipase A 2 (iPLA 2 ) from rat brain using octylSepharose, ATP-agarose, and calmodulin-agarose column chromatography steps. This procedure gave a 30,000-fold purification and yielded 4 g of a near-homogeneous iPLA 2 with a specific activity of 4.3 mol/ min/mg. Peptide sequences of the rat brain iPLA 2 display considerable homology to sequences of the iPLA 2 from P388D 1 macrophages, Chinese hamster ovary cells, and human B lymphocytes. Under optimal conditions, the iPLA 2 revealed the following substrate preference toward the fatty acid chain in the sn-2 position of phosphatidylcholine: linoleoyl Ͼ palmitoyl Ͼ oleoyl Ͼ arachidonoyl. The rat brain iPLA 2 also showed a head group preference for choline Ն ethanolamine ӷ inositol. The iPLA 2 is inactivated when exposed to pure phospholipid vesicles. The only exception is vesicles composed of phosphatidylcholine and phosphatidylinositol 4,5-bisphosphate. Studies on the regional distribution and ontogeny of various phospholipase A 2 (PLA 2 ) types in rat brain indicate that the iPLA 2 is the dominant PLA 2 activity in the cytosolic fraction, whereas the group IIA secreted PLA 2 is the dominant activity in the particulate fraction. The activities of these two enzymes change during postnatal development. Key Words: Ca 2ϩ -independent phospholipase A 2 -Ontogeny-Regional distribution-Purification-Peptide sequence-Substrate specificity.
Phospholipase A 2 (PLA 2 ; EC 3.1.1.4) constitutes a diverse group of enzymes that catalyze the hydrolysis of arachidonic acid and other fatty acids from the sn-2 position of phospholipids with the concomitant generation of lysophospholipids. These products act as intracellular second messengers and can be further metabolized to prostaglandins, leukotrienes, hydroxyeicosatetraenoic acids, and platelet-activating factor (Dennis, 1994) .
The PLA 2 superfamily is divided into several groups based on cellular localization, structure, and Ca 2ϩ requirements (Dennis, 1994 (Dennis, , 1997 . In particular, the group VI 80-kDa Ca 2ϩ -independent PLA 2 (iPLA 2 ) was first purified from murine P388D 1 macrophages (Ackermann et al., 1994) . Subsequently, it was cloned from P388D 1 macrophages (Balboa et al., 1997) , Chinese hamster ovary (CHO) cells, the Bürkitt human lymphoma library (Tang et al., 1997) , and human B lymphocytes (Larsson et al., 1998 ). An iPLA 2 activity has also been reported in many other cells and tissues (for review, see Ackermann and Dennis, 1995) .
Several studies have suggested that changes in PLA 2 activity occur in experimental ischemia (Edgar et al., 1982; Rordorf et al., 1991; Lauritzen et al., 1994; Owada et al., 1994; Clemens et al., 1996) , experimental spinal cord injury (Shohami et al., 1989 ), Alzheimer's disease (Gattaz et al., 1995a; Stephenson et al., 1996; Ross et al., 1998b) , and schizophrenia (Gattaz et al., 1995b) . Recently, PLA 2 has also been implicated in the apoptosis induced by Fas (Atsumi et al., 1998) and tumor necrosis factor (Wissing et al., 1997) as well as the fusion of synaptic vesicles (Nishio et al., 1996) and secretory granules (Nagao et al., 1995) with cellular membranes. In addition, lysophosphatidylcholine, one of the two products generated in the PLA 2 -catalyzed reaction, causes demyelination (Dousset et al., 1995) . Lysophosphatidylcholine is widely used in animal models for experimental demyelination, e.g., multiple sclerosis, sub-acute sclerosing panencephalomyelitis, and PelizaeusMerzbacher's disease (Bradl and Linington, 1996; Pavelko et al., 1998) . Collectively, this evidence suggests that PLA 2 forms may be involved in the pathogenesis of various disorders in the CNS.
The presence of PLA 2 activities in brain of various species has been reported in many studies (Gray and Strickland, 1982; Yoshihara and Watanabe, 1990; Rordorf et al., 1991; Hirashima et al., 1992; Ross et al., 1995) , yet there is no report on the identity, distribution, and kinetic characterization of the specific brain PLA 2 forms responsible for the activity. The occurrence of group IV Ca 2ϩ -dependent cytosolic PLA 2 (cPLA 2 ) and group II secreted PLA 2 (sPLA 2 ) in rat brain has been shown by immunological techniques (Rordorf et al., 1991; Clemens et al., 1996) and in situ hybridization (Lauritzen et al., 1994) , respectively. We have now determined the regional distribution and ontogeny of four major types of PLA 2 in rat brain. Because we have found that the iPLA 2 is the major PLA 2 activity in adult rat brain, we purified this enzyme and further characterized it.
EXPERIMENTAL PROCEDURES Materials

1-Palmitoyl-2-[1-
14 C]palmitoyl-sn-glycerol-3-phosphoryl-
14 C]linoleoyl-sn-glycerol-3-phosphorylethanolamine, and 1-stearoyl-2-[1-
14 C]-arachidonoyl-sn-glycerol-3-phosphorylinositol were purchased from Amersham. 1-Palmitoyl-2-[1-
14 C]arachidonoyl-sn-glycerol-3-phosphorylcholine was purchased from DuPont-NEN. All unlabeled phospholipids were purchased from Avanti Polar Lipids. Triton X-100 and phosphatidylinositol 4,5-biphosphate (PIP 2 ) were obtained from Calbiochem. Octyl-Sepharose was purchased from Pharmacia LKB Biotechnology. ATP-agarose, calmodulin-agarose, phenylmethylsulfonyl fluoride (PMSF), and other chemicals were purchased from Sigma Chemical Co. Dithiothreitol (DTT) was purchased from GibcoBRL. The 10% Tris-glycine gels and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) molecular weight markers were purchased from Novex.
PLA 2 assays
Triton X-100 mixed micelle assay. Unless stated otherwise, iPLA 2 activity was determined using the 1,2-dipalmitoyl-phosphatidylcholine (DPPC)/Triton X-100 mixed micelle assay. The assay contained 100 M DPPC and 400 M Triton X-100 in 100 mM HEPES (pH 7.5), 5 mM EDTA, and 2 mM DTT in a final volume of 500 l. The reactions were carried out at 40°C for 30 min, unless otherwise indicated. This temperature, as the phase transition temperature of DPPC, was selected to assure complete solubilization of this phospholipid in Triton X-100.
The DPPC/Triton X-100 mixed micelles were prepared as follows: Appropriate amounts of DPPC and 1-palmitoyl-2-[1-14 C]palmitoyl-sn-glycerol-3-phosphorylcholine (100,000 cpm per assay) were dried under a stream of N 2 gas. The dried lipid was then lyophilized for 1 h to remove the remaining organic solvent. Subsequently, it was suspended in an appropriate amount of prewarmed (50°C) assay buffer [100 mM HEPES (pH 7.5) with 5 mM EDTA] to give a 10ϫ vesicle suspension after vigorous mixing. An appropriate amount of Triton X-100 (to give a final concentration of 400 M) was added to the 10ϫ vesicle suspension and vortex-mixed. This 10ϫ mixed micelle suspension was kept in a 40°C water bath until use. Before beginning the assay, the 10ϫ mixed micelle suspension was diluted with assay buffer to give a 1ϫ mixed micelle solution with a final volume of 450 l. An appropriate amount of DTT was added to the 1ϫ mixed micelles to give the final concentration of 2 mM. Routinely, 50 l of enzyme sample was added to 450 l of substrate to start the reaction at 40°C for 30 min.
The reaction was stopped by addition of 2.5 ml of the Dole reagent (2-propanol/heptane/0.5 M H 2 SO 4 , 400:100:20, by volume) followed by vortex-mixing. The product mixture was subsequently processed according to the modified Dole assay (Davidson and Dennis, 1991) as previously described (CondeFrieboes et al., 1996) .
The substrate specificity experiments were performed under the same conditions except for the phospholipid used.
Vesicular assays. Lipid was prepared according to the general procedure described in the previous section. The phospholipid composition, which is given in the figure legends, varied depending on the experiment. Large unilamellar vesicles (LUVs) were produced by extrusion (Mayer et al., 1986 ) of a vesicle suspension through a membrane with a pore diameter of 0.2 m. Small unilamellar vesicles (SUVs) were prepared by bath-sonicating the vesicle suspension until the suspension became clear. The activity of iPLA 2 toward phospholipids was determined by the modified Dole assay as described in the previous section.
Assay conditions for various PLA 2 types. The specific assay system that differentiates the various PLA 2 forms is described in detail elsewhere . The assay for cPLA 2 contains 100 M 1-palmitoyl-2-arachidonoylphosphatidylcholine (PAPC)/PIP 2 (97:3) in 400 M Triton X-100 mixed micelles in 100 mM HEPES (pH 7.5), 2 mM DTT, 0.1 mg/ml bovine serum albumin (BSA), and 80 M Ca 2ϩ . The assay for iPLA 2 activity consists of 100 M DPPC in 400 M Triton X-100 mixed micelles in 100 mM HEPES (pH 7.5), 2 mM DTT, 5 mM EDTA, and 1 mM ATP. The assay for group IIA sPLA 2 contains 100 M 1-palmitoyl-2-linoleoylphosphatidylethanolamine (PLPE)/1-palmitoyl-2-oleoylphosphatidylserine (POPS) (1:1) SUVs in 100 mM HEPES (pH 7.5), 1 mM Ca 2ϩ , and 1 mg/ml BSA. The assay for group V sPLA 2 contains 100 M DPPC/POPS (3:1) SUVs in 100 mM HEPES (pH 7.5), 5 mM Ca 2ϩ , and 1 mg/ml BSA. These assays were used to compare the various activities, and the observed rates are reported without corrections for overlapping activities .
Regional distribution and ontogeny of various PLA 2 types in rat brain
Regional distribution of PLA 2 types in rat brain. Adult Holtzman Sprague-Dawley rats (16 weeks old) were anesthetized according to the guidelines of the National Institutes of Health. After the animal was killed, brain tissue was removed and dissected on ice. Each brain section was homogenized in 3ϫ wet weight of homogenization buffer [10 mM HEPES (pH 7.5), 1 mM EDTA, 0.34 M sucrose, and 100 M PMSF]. The homogenate was centrifuged at 100,000 g for 1 h at 4°C. The supernatant was saved and assayed for PLA 2 activities. The pellet was suspended in the same amount of homogenization buffer and assayed for PLA 2 activities.
Ontogeny of PLA 2 types in rat brain. Rat brain tissues at ages of 0, 4, 12, and 48 weeks were purchased from Harlan Bioproducts (Indianapolis, IN, U.S.A.). Each brain tissue was homogenized, centrifuged, and assayed for PLA 2 activities as described in the previous section.
Purification of rat brain iPLA 2
Preparation of homogenate. Brain tissues from 20 Holtzman Sprague-Dawley rats at 8 -10 weeks of age (Harlan Bioproducts) were homogenized with a Polytron homogenizer (Brinkmann) in 3ϫ wet weight of homogenization buffer [10 mM HEPES (pH 7.5), 1 mM EDTA, 1 mM DTT, 0.34 M sucrose, and 100 M PMSF]. The homogenate was centrifuged at 10,000 g for 1 h at 4°C. The resulting supernatant (called LS-Sup) was subjected to a 40% ammonium sulfate precipitation on ice. The suspension was centrifuged at 10,000 g for 30 min to collect the precipitated protein. The protein precipitate (called LS-P) was suspended into a minimal amount of buffer A [10 mM HEPES (pH 7.5), 1 mM Triton X-100, 1 mM EDTA, 1 mM DTT, 0.35 M NaCl, and 100 M PMSF]. Subsequently, all the column chromatography steps were performed at 4°C in a cold room.
Octyl-Sepharose. LS-P (usually between 90 and 100 ml) was loaded onto a 200-ml octyl-Sepharose column (6.5 ϫ 10 cm), previously equilibrated with 6 L of buffer A, at a flow rate of 600 ml/h. After loading, the column was washed with 1 L of buffer A at a flow rate of 600 ml/h. Subsequently, the bound protein was eluted with buffer B [10 mM HEPES (pH 7.5), 1 mM Triton X-100, 1 mM EDTA, 1 mM DTT, and 100 M PMSF] at a flow rate of 200 ml/h. ATP-agarose. The active fractions from the octyl-Sepharose column were pooled and loaded onto a 10-ml ATP-agarose column (1.2 ϫ 11.5 cm), previously equilibrated with buffer B, at a flow rate of 40 ml/h. After loading, the column was washed with 100 ml of buffer B at a flow rate of 60 ml/h. The bound protein was eluted with buffer C [10 mM HEPES (pH 7.5), 1 mM Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM ATP, and 100 M PMSF] at a flow rate of 30 ml/h.
Calmodulin-agarose. The active fractions from the ATPagarose column were pooled. CaCl 2 (aqueous) was added to a final concentration of 5 mM. The solution was then loaded onto a 1-ml calmodulin-agarose column (1.2 ϫ 2 cm), previously equilibrated with buffer D [10 mM HEPES (pH 7.5), 1 mM Triton X-100, 5 mM CaCl 2 , 1 mM DTT, 1 mM ATP, and 100 M PMSF] at a flow rate of 12 ml/h. The column was washed with 40 ml of buffer D at a flow rate of 30 ml/h, followed by a second wash with 15 ml of buffer D containing 10% glycerol at a flow rate of 30 ml/h. The bound enzyme was eluted with 10 mM HEPES (pH 7.5) with 1 mM Triton X-100, 1 mM EDTA, 5 mM EGTA, 1 mM DTT, 1 mM ATP, 10% glycerol, and 100 M PMSF at a flow rate of 20 ml/h. SDS-PAGE. Aliquots (20 l) of protein samples were mixed with 6ϫ SDS sample buffer [0.35 M Tris-HCl (pH 6.8), 30% glycerol, 10% SDS, 0.6 M DTT, and 0.12 mg/ml bromophenol blue] and loaded onto a 10% Tris-glycine gel. The gel was silver-stained as described by Hancock and co-workers (Wray et al., 1981) .
Trypsin digestion and peptide sequencing. The purified rat brain iPLA 2 was electrophoresed on a 10% Tris-glycine gel and stained with Coomassie Brilliant Blue G-250. After a destaining procedure, the 80-kDa iPLA 2 band was excised. Trypsin digestion was performed on the iPLA 2 band. The resulting peptides were separated using HPLC (Pharmacia Biotechnology Smart System). The amino acid sequences from selected peaks were determined using a Perkin-Elmer Sequencer Precise model 492 at the Scripps Research Institute (La Jolla, CA, U.S.A.).
Data analysis
Unless indicated otherwise, experiments were performed in at least two independent sets, each performed in duplicate or triplicate. Data are mean Ϯ SD (not shown when the bar size is smaller than the symbol) values. To allow for ready visualization, smooth curves were fit to the data. The statistical significance of differences was analyzed in a pairwise Student's t test for the difference of means.
RESULTS
Ontogeny of various PLA 2 types in rat brain
The levels of the iPLA 2 as well as the groups IIA and V sPLA 2 in the cytosolic fraction of the neonatal rat brain were close, i.e., ranging from 22 to 35 pmol/ min/mg (Fig. 1A ). In the cytosolic fraction, these activities diverged dramatically after birth.
The iPLA 2 activity is the dominant PLA 2 activity in the cytosolic fraction of rat brain throughout all postnatal ages (Fig. 1A) . In comparison with postnatal day 0, iPLA 2 underwent a sixfold increase in enzymatic activity to reach a plateau by 12 weeks of age. In the particulate fraction, the iPLA 2 activity also increased (Fig. 1B) .
FIG. 1.
Ontogeny of PLA 2 isoforms in rat brain. The activities of cPLA 2 (F), iPLA 2 (E), group V sPLA 2 (), and group IIA sPLA 2 (ƒ) in the (A) cytosolic and (B) particulate fractions of rat brain at different ages were determined as described in Experimental Procedures. Data are mean Ϯ SD (bars) values of at least two animals from two independent experiments. The activities of iPLA 2 in the cytosolic fraction at the age of 0, 4, and 12 weeks as well as those of iPLA 2 and sPLA 2 -IIA at the age of 0 and 4 weeks differ significantly at p Ͻ 0.05, as analyzed by Student's t test of the difference of the means.
However, this iPLA 2 activity was not a dominant one, with that of group IIA sPLA 2 being twofold higher (Fig.  1B) . It was notable that at 12 weeks of age, the activity of iPLA 2 in the cytosolic fraction was sevenfold higher than that in the particulate fraction.
The total sPLA 2 activities, i.e., groups IIA and V sPLA 2 forms, in the cytosolic fraction did not show any significant difference at any postnatal ages (Fig. 1A) . In the particulate fraction, the group IIA sPLA 2 was the major PLA 2 activity (Fig. 1B) . A near twofold increase of this activity was seen at 4 weeks after birth compared with that at postnatal day 0. This activity declined to the level of the neonatal rat brain by week 12 and maintained this level until 48 weeks of age. It should be noted that assays for groups IIA and V sPLA 2 forms show only a fourfold preference toward the designated sPLA 2 over the other one. The exact amounts of the activity of each individual sPLA 2 can be calculated from simple formulas as described elsewhere . It is clear, however, that throughout weeks 4 -48 the majority of sPLA 2 activity results from group IIA sPLA 2 .
The group IV cPLA 2 activity in both cytosolic and particulate fractions displayed the lowest PLA 2 activity at all ages (Fig. 1 ). There were no significant changes in this activity throughout postnatal development. These activities could be partially or entirely attributed to contributions from the high level of iPLA 2 in the brain. Consistently, the stimulation of PLA 2 activity toward PAPC by PIP 2 , a hallmark of cPLA 2 activity (Mosior et al., 1998) , was modest, within a factor of 2 (data not shown).
No statistical difference was found between the activity of pure PLA 2 and that of pure enzyme mixed with an equal amount of the particulate fraction in each determinant, as described in more detail elsewhere . This suggests that endogenous lipid present in the particulate fraction of brain samples exerts little effect on the PLA 2 activity measurement under the assay conditions used.
Regional distribution of various PLA 2 types in adult rat brain
Various brain regions were dissected from 16-weekold Holtzman Sprague-Dawley rats to obtain the cytosolic fractions for activity measurement. Samples were analyzed for the activity of each PLA 2 type using the selective assay system developed in our laboratory . The iPLA 2 activity was the dominant PLA 2 activity in all regions, i.e., cerebral cortex, cerebellum, hippocampus, hypothalamus, striatum, and the remaining parts of the brain (Table 1) . Among those regions assayed, striatum, hypothalamus, and hippocampus contained the highest amount of iPLA 2 activity. The cerebral cortex and cerebellum displayed the lowest iPLA 2 activity. The activities of the groups IIA and V sPLA 2 forms appear to be evenly distributed in all regions. Compared with the other PLA 2 forms, the activities of cPLA 2 were minute in the normal adult rat brain.
Purification of iPLA 2 from rat brain
To investigate further in detail the dominant PLA 2 activity in the developing rat brain, we decided to purify and characterize the iPLA 2 from rat brain. Brains of 20 rats at 8 weeks of age were homogenized and centrifuged at 10,000 g for 1 h. The resultant supernatant was subjected to 40% ammonium sulfate precipitation. The precipitated protein was subjected to octyl-Sepharose, ATPagarose, and calmodulin-agarose column chromatography steps. The elution profiles of these columns are shown in Fig. 2 . This procedure yielded protein that was at least 90% pure, had a specific activity of 4 mol/ min/mg toward DPPC/Triton X-100 mixed micelles, and represented a 30,000-fold purification. Table 2 summarizes the data from five purifications. The iPLA 2 had a molecular mass of 80 kDa as estimated from SDS-PAGE (Fig. 3) .
Peptide sequence
The purified iPLA 2 was digested with trypsin. The resultant peptides were separated through reverse-phase HPLC. Amino acid sequences from four individual peptides were determined. The sequence comparison between rat brain iPLA 2 and group VI iPLA 2 from the P388D 1 macrophage cell line, CHO cells, and human B lymphocytes is shown in Fig. 4 . Among these four peptides, the second peptide, which by homology is located in the fifth ankyrin repeat, displayed the highest percent identity (90%) with the known group VI iPLA 2 forms The cytosolic fraction of each brain region was obtained, and the activity of each PLA 2 isoform in these samples was measured using the procedures described in Experimental Procedures. Data are mean Ϯ SD values of two independent experiments, with each measurement performed in triplicate. The same anatomical brain sections from eight adult rats (16 weeks old) were pooled together and used in each experiment.
The iPLA 2 activity in cerebellum is statistically different from that in striatum, hippocampus, hypothalamus, and the rest of the brain at p Ͻ 0.05, as analyzed by Student's t test for the difference of the means. (Fig. 4B) . The fourth peptide, which is located at the carboxyl terminus of the known group VI iPLA 2 forms, also showed high homology (Fig. 4D) . The third peptide, which is located downstream of the lipase consensus domain (GXS 465 XG) of the known group VI iPLA 2 forms, also revealed considerable homology (Fig. 4C) . The first peptide (Fig. 4A) , which is located at the amino terminus of the known group VI iPLA 2 forms, displayed the lowest homology to all known group VI iPLA 2 forms. The highest diversity among the known group VI iPLA 2 forms is observed in this region as well. Results from the peptide sequencing suggest that the rat brain iPLA 2 is likely to be a variant of the known group VI iPLA 2 forms.
Substrate presentation and assay optimization
The activities of all the phospholipases studied to date display a dramatic dependence on the physical state of the phospholipid substrates. The most commonly used phospholipid aggregates are LUVs, SUVs, and mixed micelles. The rat brain iPLA 2 exhibited nonlinear kinetics with both 1-palmitoyl-2-linoleoylphosphatidylcholine (PLPC; Fig. 5A ) and DPPC (Fig. 5B ) in both LUVs and SUVs. The hydrolysis ceased after several minutes. In contrast, the hydrolysis of both PLPC (Fig. 5A) and DPPC (Fig. 5B ) in mixed micelles was linear for at least up to 0.5 h. Consequently, mixed micelles appear as the preferred substrate form for the characterization of the kinetics, substrate specificity, and inhibitors of iPLA 2 .
Inactivation of iPLA 2 by vesicles
As demonstrated above, iPLA 2 hydrolyzed vesicular forms of phospholipid poorly, and the reaction stopped after several minutes (Fig. 5) . There are at least two possible explanations for this kinetic property. First, the enzyme could be trapped on the vesicles and able to hydrolyze only substrate within its immediate surroundings. This mechanism of inhibition was proposed, among others, for the human nonpancreatic sPLA 2 (Bayburt et al., 1993) and the group IV cPLA 2 (Burke et al., 1995; Bayburt and Gelb, 1997) . Under these circumstances, the solubilization of the lipid vesicles with Triton X-100 to form mixed micelles should allow the release of the enzyme from lipid vesicles and restore full enzymatic activity. Second, the enzyme could be denatured or inactivated through its interaction with the lipid vesicles. In this case, the incubation of iPLA 2 with pure phospholipid vesicles could result in the permanent loss of enzymatic activity. In this case, the addition of Triton X-100 would not lead to the recovery of enzymatic activity.
We conducted the following experiment to determine which hypothesis applies to the iPLA 2 . Pure iPLA 2 was incubated with 100 M PLPC LUVs or SUVs for the designated time at 40°C. At this point 400 M Triton X-100 (final concentration) was added to the enzymephospholipid vesicle mixture to solubilize the phospholipid vesicles into mixed micelles. The solutions were then incubated for an additional 30 min at 40°C. The enzymatic activity remaining after the additional incubation with solubilized mixed micelles converted from vesicles is presented in Fig. 6 as relative percent activity with regard to the enzymatic activity obtained in the standard mixed micellar assay (defined as 100%). As shown in Fig. 6 , the enzymatic activity declines as the incubation time increases with either PLPC LUVs or SUVs. Albumin is known to extract products-lysophospholipid and free fatty acid-from lipid vesicles and
FIG. 2. Elution profiles of iPLA 2 on (A) octyl-Sepharose, (B)
ATP-agarose, and (C) calmodulin-agarose. The second activity peak from octyl-Sepharose (A) was used in the subsequent ATP-agarose column chromatography. The eluted active fractions from the ATP-agarose column were chromatographed through calmodulin-agarose. The solid line represents the UV trace at 280 nm. The iPLA 2 activity (F) of each fraction was determined as described in Experimental Procedures.
therefore could prevent a possible product inhibition. However, inclusion of 1 mg/ml BSA in the vesicular assays did not have any protective effect on the iPLA 2 activity (data not shown).
To investigate further this unique property, we studied the effect of anionic lipid in pure PAPC vesicles on the activity of rat brain iPLA 2 . Anionic lipids, e.g., phosphatidylserine and PIP 2 , are known to enhance the enzymatic activity of pancreatic sPLA 2 (Berg et al., 1997) and cPLA 2 (Leslie and Channon, 1990; Bayburt and Gelb, 1997; Mosior et al., 1998 ). Therefore, we tested the effect of 3 mol% PIP 2 in PAPC SUVs on the activity of iPLA 2 (Table 3 ). Inclusion of 3 mol% PIP 2 in PAPC vesicles resulted in a 10-fold larger release of arachidonic acid after a 30-min incubation at 40°C, when compared with that toward pure PAPC vesicles (Table  3) . It is important that the iPLA 2 displayed a linear lipid hydrolysis on PAPC/PIP 2 (97:3) SUVs with a specific activity of 8.6 mol/min/mg. It is notable that there was no loss of enzymatic activity after the iPLA 2 was preincubated with PAPC/PIP 2 (97:3) SUVs for 5 min at 40°C (data not shown). In contrast, PAPC/POPS (3:1) SUVs did not protect the iPLA 2 from being inactivated by lipid vesicles or improve the linearity of the time course of substrate hydrolysis (Table 3) .
Substrate specificity
As demonstrated above, the phospholipid/Triton X-100 mixed micelles proved to be the preferred form of substrate for the kinetic studies of iPLA 2 . Therefore, we used this form of substrate to investigate, under optimal conditions, i.e., 100 M phospholipid and 400 M Triton X-100, the specificity of iPLA 2 toward various phospholipids. As illustrated in Table 4 , the preference of iPLA 2 for the sn-fatty acids of phosphatidylcholine was linoleoyl Ͼ palmitoyl Ͼ oleoyl Ͼ arachidonoyl. The fivefold preference for linoleoyl over arachidonoyl is opposite to the preference displayed by cPLA 2 for the same phospholipids when assayed under identical conditions (except for the addition of 0.2 mM Ca 2ϩ ). The cPLA 2 preferred arachidonoyl 10-fold over linoleoyl Detailed conditions for each purification procedure are given in Experimental Procedures. Typically, 20 rat brains were used in each purification batch. Data are average Ϯ SD values of five individual purification assays.
FIG. 3.
Silver-stained SDS-PAGE of protein from each purification step. Lanes 1-9 contain molecular mass markers, 30 l of the pool from the octyl-Sepharose column, 30 l of fractions 27-32 from the calmodulin-agarose column, and molecular mass markers, respectively.
FIG. 4.
Sequence alignment of rat brain iPLA 2 with other known iPLA 2 forms. The purified rat brain iPLA 2 from two consecutive purification assays was pooled, concentrated, and digested with trypsin. The resultant peptides were separated by reverse-phase HPLC. The amino acid sequences of four of these peptides were determined. A-D: The sequences of these four peptides were aligned with known iPLA 2 forms from the P388D 1 macrophage cell line, Chinese hamster ovary cells, and human B lymphocytes. RAT BRAIN Ca 2ϩ -INDEPENDENT PHOSPHOLIPASE A 2 (data not shown). Among the head groups studied, iPLA 2 demonstrated a twofold preference for choline over ethanolamine with the same fatty acids in both the sn-1 and sn-2 positions. The iPLA 2 acted poorly on lipids with the inositol head group (Table 4) .
DISCUSSION
Regional distribution and ontogeny of various PLA 2 types in rat brain
Our results indicate that iPLA 2 is subjected to developmental changes. The activity of iPLA 2 increases rapidly in the developing rat brain after birth and peaks at the age of 12 weeks. Because the activity of iPLA 2 in vivo could not be assessed from these experiments, the physiological significance of the changes in iPLA 2 activity reported here is uncertain. However, this is also the period of intensive changes in lipid metabolism. Therefore, this suggests a possible involvement of iPLA 2 in those processes, like synaptogensis, glial proliferation, and myelination (Aghajanian and Bloom, 1967) , that are likely to require intensive lipid remodeling (Dussault and Ruel, 1987; Jacobson, 1991) . In adulthood, iPLA 2 is the dominant PLA 2 activity in all regions of rat brain, with the highest levels in hippocampus and striatum. In contrast, the other cytosolic PLA 2 , group IV cPLA 2 , shows the lowest activity among the four enzymes studied. This is consistent with the earlier reports on the low level of cPLA 2 in brain (Yoshihara et al., 1992; Clemens et al., 1996; Stephenson et al., 1996) due to a developmental down-regulation (Yoshihara et al., 1992) . The highest level of cPLA 2 was found at embryonic day 12. This activity declined to and was sustained at the lowest level after birth through adulthood. However, elevated levels of cPLA 2 were found in several neurological disorders Stephenson et al., 1996) . Collec-
FIG. 5.
Time course of substrate hydrolysis by iPLA 2 . PLPC (A) or DPPC (B) (100 M each) was prepared in the form of SUVs (ᮀ), LUVs (OE), or Triton X-100 (400 M) mixed micelles (F) as described in Experimental Procedures. The iPLA 2 activity was determined toward each substrate form after incubation for the indicated time at 40°C. Data are mean Ϯ SD (bars) values from at least three independent experiments, each performed in duplicate.
FIG. 6.
Effects of preincubation with pure PLPC vesicles on the activity of iPLA 2 . iPLA 2 was preincubated with 100 M PLPCLUVs (F) or -SUVs (OE) in 100 mM HEPES (pH 7.5) with 5 mM EDTA and 2 mM DTT for the indicated time at 40°C. Subsequently, Triton X-100 was added to the enzyme-lipid vesicle mixture (to a final concentration of 400 M), and the reaction was continued for 30 min at 40°C. Results are expressed as the percent activity at each time point relative to the specific activity obtained from the mixed micellar assay. Data are mean Ϯ SD (bars) values of two independent experiments, each performed in duplicate. The enzymatic reaction was performed at 40°C for 30 min with the modified Dole assay (as described in Experimental Procedures). Data are mean Ϯ SD values of at least three independent experiments, each performed in duplicate. POPC, 1-palmitoyl-2-oleoylphosphatidylcholine; SAPI, 1-stearoyl-2-arachidonoylphosphatidylinositol. tively, our results suggest that iPLA 2 may play a role in the ontogeny of phospholipid metabolism of the brain during postnatal development.
It has to be noted that although the amount of iPLA 2 in the brain cytosol is much higher than that of other PLA 2 forms, the actual activity of this enzyme in vivo may be a subject of regulation, as discussed below.
A recent report on the distribution of PLA 2 activity in human brain suggested a nearly uniform distribution of iPLA 2 activity among brain regions, except for substantia nigra (Ross et al., 1998a) . However, this activity is not likely to be associated with the 80-kDa iPLA 2 purified from rat brain and described here. This enzyme is quickly deactivated by substrate organized in the form of vesicles (Fig. 5) , which was used to determine the distribution of PLA 2 activity in the human brain by Ross et al. (1998a) .
It has to be noted that other iPLA 2 forms may be also present in brain tissues, e.g., the recently discovered cPLA 2 -␥ (Underwood et al., 1998; Pickard et al., 1999) . However, the latter enzyme is primarily associated with the particulate fraction (Underwood et al., 1998) and displays low enzymatic activity (Pickard et al., 1999) . Thus, this novel isoform of cPLA 2 is not likely to make any significant contribution to the iPLA 2 activity in cytosolic fractions of any brain region and the developmental age reported here.
Purification of rat brain iPLA 2
The rat brain iPLA 2 described here is the first PLA 2 purified from brain tissues with a confirmed amino acid sequence, even though several studies have shown the presence of PLA 2 forms in various brain tissues (Gray and Strickland, 1982; Yoshihara and Watanabe, 1990; Hirashima et al., 1992; Ross et al., 1995; Nègre-Aminou et al., 1996) . Of course, amino acid sequences of other PLA 2 forms purified from other sources but present in brain tissues have been reported, e.g., cPLA 2 . This iPLA 2 has a molecular mass of 80 kDa estimated by SDS-PAGE. The search for homologous sequences in the currently available protein databases yielded only those of the closely related group VI iPLA 2 forms from P388D 1 macrophages, CHO cells, pancreatic islets, and human B lymphocytes and of the human ankyrin proteins. These results suggest that the rat brain iPLA 2 belongs to the group VI iPLA 2 in the PLA 2 superfamily (Dennis, 1997) .
The rat brain iPLA 2 reported herein differs significantly from the bovine brain iPLA 2 activity that has been reported (Hirashima et al., 1992) . First, these enzymes show different substrate specificity. The rat brain iPLA 2 displays little activity toward plasmalogen, which is the preferred substrate for the bovine brain iPLA 2 , in the Triton X-100 mixed micellar assay (Wang et al., 1999) . Second, they have different molecular masses as determined by SDS-PAGE. Rat brain iPLA 2 in the purified or partially purified form was sensitive to the presence of Triton X-100 in solution. Attempts to remove Triton X-100 from the purified iPLA 2 resulted in the partial loss of activity. A similar property was also reported for the iPLA 2 from rabbit kidney (Portilla and Dai, 1996) . Triton X-100 may stabilize the enzyme through hydrophobic interactions between the enzyme and Triton X-100 micelles. Accordingly, the purification procedures were carried out in the presence of 1 mM Triton X-100 in all buffers. The purified protein was stored in a buffer containing 1 mM Triton X-100 at Ϫ20°C. Under those conditions, the pure enzyme is stable for at least 2 months.
Dependence of rat brain iPLA 2 on properties and composition of membranes
The hydrolysis by iPLA 2 of pure phospholipids in either LUVs or SUVs was greatly attenuated after a few minutes at 40°C. The nonlinear time courses for vesicle hydrolysis are not unique to iPLA 2 . They have also been reported for human sPLA 2 and cPLA 2 forms (Ghomashchi et al., 1992) . This attenuation of enzymatic activity was attributed to the trapping of the enzyme in a domain enriched in hydrolysis products. However, this is clearly not the case with iPLA 2 , because the inclusion of bovine serum albumin in the reaction mixture did not protect the enzyme from being inactivated by pure phospholipid vesicles. The loss of activity was irreversible and could not be restored by the conversion of vesicles to mixed micelles with addition of Triton X-100. Therefore, the iPLA 2 appears to be irreversibly inactivated when exposed to certain pure phospholipid vesicles, rather than being kinetically inactivated in the phospholipid vesicles.
It is interesting that this inhibitory effect was not observed with PAPC/PIP 2 SUVs. This notable exception suggests that under specific conditions (lipid composition and/or membrane structure), iPLA 2 is capable of sustained high-level activity toward membranes. This is likely an effect of PIP 2 on the physical state of the phospholipid vesicles because iPLA 2 does not appear to contain a pleckstrin homology domain, as does cPLA 2 (Mosior et al., 1998) . This putative change in the combination with the high curvature of SUVs may allow for the full enzymatic activity. It is clear that the artificial vesicles lack many components found in natural membranes. Thus, some of these components, like PIP 2 , may allow the iPLA 2 to express its full activity in natural membranes. The search for these components for iPLA 2 could be crucial for understanding the function and regulation of iPLA 2 in vivo. It is important that it has been recently suggested that the involvement of group VI iPLA 2 in Fas-induced apoptosis may result from changes of the physical and/or chemical properties of cellular membranes, which lead to the activation of the enzyme (Atsumi et al., 1998) . Furthermore, changes of the physical and/or chemical properties of synaptic vesicles (Nishio et al., 1996) and secretory granules (Nagao et al., 1995) induced by the activity of PLA 2 promote the Ca 2ϩ -independent fusion of these vesicles with cellular membranes. RAT BRAIN Ca 2ϩ -INDEPENDENT PHOSPHOLIPASE A 2
Substrate specificity
The substrate specificity studies suggest that iPLA 2 prefers linoleoyl fivefold over arachidonoyl in the sn-2 position of phosphatidylcholine. This preference was not previously reported for other iPLA 2 forms. On the other hand, under similar experimental conditions, cPLA 2 exhibited a 10-fold preference for arachidonoyl over linoleoyl in the sn-2 position of PC. As suggested by others (Kramer et al., 1991) , cPLA 2 is an arachidonic acidselective PLA 2 and an important enzyme in arachidonic acid metabolism. Thus, iPLA 2 could be an important enzyme in linoleate metabolism.
Elevation of PLA 2 activity ) and loss of linoleate (Chajes et al., 1995) from membrane phospholipids were reported in various types of cancer. In addition, linoleate (Tillotson et al., 1994) and linoleate metabolites Glasgow, 1991, 1994; Glasgow et al., 1992 Glasgow et al., , 1997 Eling et al., 1995) induce cell proliferation in tumor cells and fibroblasts. It would be interesting to study the possible involvement of iPLA 2 in these processes.
In summary, using in vitro PLA 2 assays, we have shown that iPLA 2 is the major PLA 2 activity in the cytosolic fraction of developing and adult rat brain, whereas the group IIA sPLA 2 is the dominant enzyme in the particulate fraction. The substrate specificity studies suggest that the rat brain iPLA 2 could be an important enzyme in the linoleic acid metabolism. This enzyme is regulated by the physical properties and composition of membranes. It is important to investigate further the function and regulation of the iPLA 2 in the CNS, as well as its involvement in neurological disorders.
